Page 16 - Cipla

Coronavirus vaccine update: Moderna vaccine trial delayed, India's by Aug15

Coronavirus vaccine latest update: A large trial of Moderna Inc's potential coronavirus vaccine has been delayed, as the company makes changes to its study plan. Catch latest updates on Covid vaccine

Cipla, Boehringer Ingelheim to co-sell 3 oral anti-diabetic drugs in India

Pharma major Cipla and drug firm Boehringer Ingelheim India on Monday announced partnership to co-market three new oral anti-diabetic drugs in the country. The companies have entered into a partnership for co-marketing three new oral anti-diabetics drugs --- Oboravo (Empagliflozin),Oboravo Met (Empagliflozin+Metformin) and Tiptengio (Empagliflozin+Linagliptin) in India, Cipla and Boehringer Ingelheim India Pvt Ltd said in a statement. As per the International Diabetes Federation, India is home to 7.7 crore diabetic adults aged between 20-79 years, ranking second behind China, and is poised to reach 13.42 crore patients by 2045, it added. "Diabetes continues to be a focus area for Cipla and with a strategic partnership with Boehringer Ingelheim coupled with our strong brand building, patient access and reach capabilities, we will be at the forefront of providing holistic diabetes care," Cipla India Business Executive VP & CEO Nikhil Chopra said. In a similar vein, Boehringer ...

Coronavirus vaccine update: AstraZeneca, Modena leading the race, says WHO

Coronavirus vaccine latest update: The University of Oxford and AstraZeneca Plc.'s experimental vaccine is the first to enter the final stages of clinical trial. Catch latest updates on Covid vaccine

India's coronavirus drug market set for price war as firms ready launches

Sources say Cipla-BDR's favipiravir will be at least 30 per cent cheaper than Glenmark's price of Rs 103 per tablet. Cipla did not confirm.

A pricing war? Cipla pips Hetero, fixes remdesivir under Rs 5,000

A senior government official said it is in wait-and-watch mode and has not decided to take any suo motu action on the pricing of the drug

Cipla to price Covid-19 drug remdesivir at less than Rs 5,000 per vial

Hyderbad-based drug firm Hetero on Sunday said that it will price its generic version of the drug in the range of Rs 5,000-6,000 per dose

Can't call Remdesiver, Favipiravir game changers in Covid-19 fight: Experts

Glenmark Pharmaceuticals has launched the antiviral drug Favipiravir, while Cipla and Hetero have received approvals from the Drug Controller General of India to launch Remdesivir

Cipla hits 52-wk high on launch of generic remdesivir for Covid-19 patients

Remdesivir is the only USFDA approved emergency use authorization treatment in severe (hospitalised) Covid-19 patients.

Hetero to launch remdesivir at Rs 5,000-6,000/dose, Cipla to follow suit

Industry sources estimate that at least 10,000 patients need the drug urgently in the areas with high case load

Covid-19 crisis: Cipla launches generic remdesivir under brand name Cipremi

The USFDA had issued an Emergency Use Authorization (EUA) to Gilead Sciences Inc for emergency use of remdesivir for the treatment of Covid-19 patients

Covid-19 crisis: Made-in-India remdesivir may come by end of June

Currently, the drug is allowed for "restricted emergency use" on severely ill hospitalised Covid patients in India.

Roche Pharma India expands partnership with Cipla for oncology medicines

The two companies had previously entered into a similar agreement in February 2018 for promotion and distribution of tocilizumab (Actemra) and other products

Covid-19 crisis: Gilead working on combo of remdesivir, other drugs

Patient recruitment for the tocilizumab combination therapy study will begin this month.

US respiratory pipeline breathes in fresh optimism for Cipla; stock up 5%

Improving growth in North America will complement strong domestic sales

Cipla working on multiple therapies to fight spread of coronavirus

Besides, the company is reworking its domestic market sales strategy, and scrutinising its capital and operating expenditure plans

Cipla's profit before tax dips 35% to Rs 327.9 cr; India business grows 12%

The net profit came down 33 per cent to Rs 246 crore, lower than Street expectations. Emkay Global had expected a 3 per cent dip in profit for the quarter.

MARKET WRAP: Indices end flat, Sensex slips 25 pts; financials, autos fall

All that happened in the markets today

Market Ahead, May 15: All You Need To Know Before The Opening Bell

Today, a total of 12 companies including Cipla, Aaarti Drugs, and M&M Finance are scheduled to announce their results

Indian drug makers gear up to make Gilead's remdesivir for Covid-19 therapy

Domestic players will be free to price it; Dutch firm Mylan also to make the drug in India; no royalty for Gilead as yet

Gilead enters licensing pact with 5 drug firms in India, Pak for remdesivir

According to the agreement the companies Cipla, Hetero Labs, Jubilant Life Sciences, Mylan, and Pakistan based Ferozsons Labs, to manufacture and sell remdesivir in 127 countries